BCL2 and plasma cell myeloma: A similar observation has been made with the full-length proteins, and was explained by the fact that Noxa and Bad neutralise only a subset of anti-apoptotic Bcl-2 proteins.12 To test pepNoxa's apoptotic potential, a U266 myeloma cell line was used, whose survival is dependent on Mcl-1.30 However, expression of pepNoxa in this cell line was not sufficient to drive apoptosis, as viability was unaffected and PARP was not cleaved (Figure 6a).